Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure due to a potential error at the manufacturing site.
Similar Posts
MHRA approves zanidatamab (Ziihera) for the treatment of biliary tract cancer
Zanidatamab is used when the cancer cannot be removed by surgery and has spread to nearby tissues or other parts of the body.
BD BodyComm™ version 3.3 software used for BodyGuard infusion pumps, BodyGuard-T and T34 syringe drivers: Important steps to manage transition to Windows 11 (DSI/2025/006)
The BodyComm software currently uses Windows 10. Microsoft is transitioning to Windows 11 from 14 October 2025 which requires an updated cable to connect the pumps to the BodyComm software. These cables may not be available until after the Windows transition date.
Field Safety Notices: 6 October to 10 October 2025
List of Field Safety Notices from 6 October to 10 October 2025.
Field Safety Notices: 4 to 8 August 2025
List of Field Safety Notices from 4 to 8 August 2025.
Guidance: COVID-19 test validation approved products
Find out which COVID-19 test products have been approved.
Fast, Expert and Open – how the MHRA is poised to become a global leader in risk-proportionate regulation
New MHRA CEO puts safety, accelerated access and innovation at the centre of agency’s refreshed strategic direction.